CDTTWHIGH SIGNALFINANCIAL10-K

CDTTW executed four reverse stock splits within 14 months while operating cash flow deteriorated substantially, signaling severe financial distress.

The company's execution of multiple reverse stock splits (1-for-100, 1-for-15, 1-for-8, and 1-for-25) indicates extreme share price weakness and potential exchange listing compliance issues. The dramatic deterioration in operating cash burn combined with only modest asset growth suggests the company is rapidly consuming capital while struggling to maintain operational funding.

Comparing 2026-04-15 vs 2025-03-28View on EDGAR →
FINANCIAL ANALYSIS

The company's financial position shows mixed signals with current assets growing to $4.4M and total assets expanding to $5.7M, though this was accompanied by higher liabilities reaching $12.8M. Operating cash flow burned substantially more capital year-over-year, while R&D expenses approached $5.1M, indicating continued investment in development programs. The overall picture reveals a capital-intensive biotech burning through funds at an accelerated pace while attempting to maintain compliance with exchange listing requirements through aggressive stock consolidation measures.

FINANCIAL STATEMENT CHANGES
Current Assets
Balance Sheet
+61.3%
$2.7M→$4.4M

Current assets grew 61.3% — improving short-term liquidity or inventory/receivables build.

Operating Cash Flow
Cash Flow
-60.7%
-$9.7M→-$15.6M

Operating cash flow fell 60.7% — earnings quality concerns; investigate working capital changes and non-cash items.

R&D Expense
P&L
+49.6%
$3.4M→$5.1M

R&D investment increased 49.6% — signals commitment to future product development, though near-term margin impact.

Total Assets
Balance Sheet
+34.7%
$4.2M→$5.7M

Asset base grew 34.7% — expansion through organic growth, acquisitions, or capital deployment.

Current Liabilities
Balance Sheet
+19.4%
$10.7M→$12.8M

Current liabilities rose 19.4% — increased short-term obligations, watch current ratio.

Total Liabilities
Balance Sheet
+16.7%
$11.0M→$12.8M

Liabilities increased 16.7% — monitor debt-to-equity ratio and interest coverage.

LANGUAGE CHANGES
NEW — 2026-04-15
PRIOR — 2025-03-28
ADDED
The aggregate market value of the common stock held by non-affiliates of the registrant as of June 30, 2025, the last business day of the registrant s most recently completed second fiscal quarter, was $ 552.00 based upon the closing price reported for such date on The Nasdaq Capital Market.
On January 24, 2025, May 19, 2025, October 10, 2025 and March 26, 2026, the Registrant effected 1-for-100, 1-for-15, 1-for-8 and 1-for-25 reverse stock splits of its authorized shares of common stock, respectively.
Each reverse stock split was accompanied by a corresponding decrease in its issued and outstanding shares of common stock.
We may issue additional shares of common stock or preferred stock, including issuances upon exercise of outstanding pre-funded warrants, in connection with capital raising transactions and under an employee incentive plan, which issuances would significantly dilute the interest of our stockholders.
Business Overview CDT Equity Inc., formerly Conduit Pharmaceuticals Inc., a Delaware corporation ( CDT , CDT Equity or the Company ), is a data-driven pharmaceutical development, focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships.
+7 more — sign up free →
REMOVED
The aggregate market value of the common stock held by non-affiliates of the registrant as of June 28, 2024, the last business day of the registrant s most recently completed second fiscal quarter, was $ 41,401,162 based upon the closing price reported for such date on The Nasdaq Global Market.
On January 25, 2025, the Registrant effected a 1-for-100 reverse stock split of its authorized shares of common stock, accompanied by a corresponding decrease in its issued and outstanding shares of common stock.
It is difficult to accurately predict the time and cost of development and of subsequently obtaining regulatory approval for AZD1656 as it employs newly developed technology.
We currently rely on agreements with a related party and third parties for the purpose of licensing our clinical assets.
In the near-term, we intend to rely on third parties for the licensing of clinical assets and those which may arise through future partnerships.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →